Συνημμένο έγγραφο 4β

Researcher’s Curriculum Vitae
PERIKLIS PAPPAS
Personal
Born June 28, 1965, Ioannina, Greece. Married; three children.
Employment
January-February 1992; Research Fellow at the “Catherine Griffiths Cancer Research Laboratory” of the Medical Oncology Unit of Westminster Hospital (MTT and other clonogenic assays). June-August 1996; Research Fellow (two months) at the Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, USA (Tissue-specific expression of rat ALDH3 gene). August-September 2000; Research Fellow (two weeks) at the Toxicology Research Unit, Medical School, University of Tampere, CIMO Tampere, Finland (Isolation, collection and culturing Muller cells and other retinal cells). 1998 – 2004; Elected Lecturer in Pharmacology, Medical School, University of 2004 – presence; Elected Assistant Professor in Pharmacology, Medical School, Teaching
• 1998-presence: Medical School, University of Ioannina. 3rd year’s students. “Medical Pharmacology”, “Basic Pharmacokinetics”, “Toxicology”.
• 2000-2003: Department of Biochemistry, University of Ioannina. 3rd year’s students “Biochemical and Molecular Pharmacology”,
• 2003-2008: University of Ioannina. Post-graduate Program of Certification on Agricultural Products’ Quality, “Quality and Environment – II”.
• 2006-presence: Department of Biological Applications and Technology, University of Ioannina. 4th year’s students. “Biochemical and Molecular
Toxicology”.
Participation in International Congresses (last 10 years)
• 4th Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries, 12- • 10th International Workshop of Enzymology and Molecular Biology of Carbonyl Metabolism, July 1-5, 2000, Taos, New Mexico, USA. • 39th Congress of the European Society of Toxicology, September 13-16, 2001, • 5th Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries, May 29 – June 1, 2002, Constanta, Romania. • 11th International Workshop of Enzymology and Molecular Biology of Carbonyl Metabolism, July 2-7, 2002, Ystad, Sweden. • European Congress on Biomedical Research of Alcoholism, September 11-14, • International Course on Pharmacokinetic-Pharmacodynamic Modelling Concepts and Applications, Leiden/Amsterdam Center for Drug Research October 12-15, 2003, Leiden/Amsterdam, The Netherlands. • 16th International Congress on Anticancer Treatment, February 1–4, 2004, • Intermediate Level Workshop on Pharmacokinetic/Pharmacodynamic Data Analysis: A Hands-on Course Using WinNonlin, September 20–23, 2004, Nice, France. • 13th European Cancer Conference, 30 October – 3 November 2005, Paris, • 18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”, November 7-10, 2006, Prague, Czech Republic. • Targeting Protein-Protein Interactions: Design Principles and Therapeutic Value, July 14-15, 2007, Kuopio, Finland. • 20th Meeting of the European Association for Cancer Research (EACR), 5-8 • 33rd European Society for Medical Oncology Congress, September 12-16, • 7th International Symposium on Targeted Anticancer Therapies (TAT), March 23-25, 2009, Amsterdam, The Netherlands. • 39th Annual European Society for Dermatological Research (ESDR) Meeting, • 21st Meeting of the European Association for Cancer Research (EACR), 26-29 • 40th Annual European Society for Dermatological Research (ESDR) Meeting, Scientific Award: Data Base for personal PC, with all the drugs of the Greek market.
Member of Scientific Societies
Member of Organizing Committees
Techniques: gDNA, mRNA, cDNA, qRT-PCR, western blotting, design of primers,
migration and wound healing assays, cloning, transfection and reporter assays, in vitro
activation, confocal microscope, in vitro cytotoxicity tests (WST-1, MTS assays),
mutagenicity, cell culturing, primary and stable cancer cell lines, isolation of human
endothelial cells (HUVEC), nuclear – cytosolic – microsomal extracts, drug levels –
pharmacokinetics in biological fluids (HPLC, atomic absorption spectroscopy, gass
chromatography, GCMS), ELISA, RIA. Animal handling.
Participation in Research Grants
1992-1994; Research Fellow in: “Cell Injury and Defense Mechanisms” as part of 1996-1999: Principal investigator in: “Phenobarbital mechanism of action in two genetically modified rat substrains”, funded by the Greek Ministry of Infrastructure, Research & Technology. 1997-2000: Principal investigator in: “In vitro Oculotoxicity – BIOMED II”, 2005-2007: “Study on the effects of specific COX-2 inhibitors on CNS of rats”, supported by the Greek Ministry of Infrastructure (60,000 euro). 2006-2008: “Drug metabolizing protein expressions in brain tumors. Resistance in chemotherapy and prognostic markers” funded by the Greek Ministry of Health (15,000 euro). Personal Funded Grants
• “Biochemical parameters of the skin and sun radiation. Possible toxicity markers of UV radiation of the skin”. Research Committee of UoI 2001-2002 (5,870 euro). • “Corneal, pterygium and retinal biochemical parameters. Evaluation of ocular drug toxicity with in vitro techniques” Greek Ministry of Health 2001-2003 (7,340 euro). • “Regulation of aldehyde dehydrogenases by the nuclear receptors CAR and PXR in Wistar rats genetically selected for phenobarbital inducibility” Heraklitos 2010-2013 (45,000 euro).

PUBLICATIONS
Full papers: 32
Citations: 220

Abstracts
1. Karageorgou M, Vasiliou V, Pappas Ρ, Marselos M: Enhancement of aldehyde dehydrogenase activity by diethylstylbestrol in the liver of Wistar rat. Ρharmacology & Τoxicology 67, Suppl 1, Ρ22, 1990. 2. Marselos M, Vasiliou V, Kafetzopoulos Ε, Pappas Ρ: Differential response to centrally acting drugs between two rat substrains selected for the inducibility of aldehyde dehydrogenase in the liver. Ρharmacology & Τoxicology 67, Suppl 1, Ρ23, 1990. 3. Ρappas Ρ, Stephanou Ρ, Vasiliou V, Marselos Μ: Drug metabolism in the rat liver after exposure to α pyrogenic inflammatory agent. Ρharmacological Research 31, Suppl 1, 49, 1995. 4. Marselos M, Ρappas Ρ, Stephanou Ρ, Vasiliou V: Different biochemical and pharmacological responses in two substrains of the Wistar rat. Ρharmacological Research 31, Suppl 1, 171, 1995. 5. Pappas P, Stephanou P, Vasiliou V and Marselos M: Genetic differences in phenobarbital inducibility of two rat substrains. Fundamental & Clinical Pharmacology 13, Suppl 1, 1999. 6. Pappas P, Karamanakos PN, Gousia P, Marselos M: Time-response effects of LPS on several neuro-biochemical parameters of rat liver and brain. Toxicol Letters, 123, Suppl 1, 63, 2001. 7. Gousia P, Pappas P, Karamanakos PN, Marselos M, Hatzinikolaou DG, Psallidopoulos M, Stavridou A: CNS effects in the rat of alcoholic beverages exposed to electromagnetic radiation. Toxicol Letters, 123, Suppl 1, 64, 2001. 8. Mannerstrom M, Zorn-Kruppa M, Toimela M, Maenpaa H, Salminen L, Pappas P, Tahti H: The cytotoxicity of selected systemic and eye drugs in retinal pigment epithelial cell cultures. Toxicol Letters, 123, Suppl 1, 104, 2001. 9. Karamanakos PN, Pappas P, Marselos M: Disulfiram-like effects of commonly prescribed antibiotic agents. Toxicol Letters, 123, Suppl 1, 105, 2001. 10. Pappas P, Yfanti F, Karamanakos PN, Nikolaidou M, Marselos M: Neurochemical changes of D-glucuronolactone in Wistar rat brain. Alcohol and Alcoholism 2003, 38(5). 11. Briasoulis E, Tolis C, Pappas P, Marselos M, Nicolaides C, Nikiforidis L, Nikolaidou M, Siarabi O, Tzamakou E, Pavlidis N: Metronomic oral vinorelbine (MOVIN): a dose establishing translational and pharmacokinetic study in patients with metastatic refractory cancer. European Journal of Cancer Supplements 2005, 3(2):422. 12. Pentheroudakis G, Golfinopoulos V, Karina M, Pappas P, Nikiforidis L, Nicolaidou M, Tzamakou E, Marselos M, Fountzilas G, Pavlidis N: Weekday on - weekend off oral capecitabine: a Phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy. European Journal of Cancer Supplements 2005, 3(2):422. 13. Pappas P, Biziota E, Marselos M, Briasoulis E. Evaluation of antiproliferative and molecular effects of vinorelbine and its active metabolite 4-O-deacetyl-vinorelbine on human endothelial cells in an in vitro simulation model of metronomic chemotherapy. European Journal of Cancer Supplements 2008, 6(9):138. 14. Briasoulis E, Kalofonos H, Samantas E, Varthalitis I, Syrigos KN, Fountzilas G, Pappas P, Sainis I, Puozzo C, Pavlidis N. Metronomic oral vinorelbine in patients with recurrent breast, prostate or non-small cell lung cancer: optimal dose-finding trial of the hellenic cooperative oncology group. Annals of Oncology 2008, 19(S8):163. 15. Pappas P, Biziota E, Marselos M, Briasoulis E. Low dose metronomic treatment elicits the anti-angiogenic profile of vinorelbine in an in vitro model of human endothelial cells. Annals of Oncology 2009, 20(S3):32. 16. Gaitanis G, Pappas P, Magiatis P, Mexia N, Galanou M, Stathopoulou K, Skaltsounis AL, Marselos M, Velegraki A, Bassukas ID. The seborrheic dermatitis associated Malassezia indoles induce the Aryl-hydrocarbon receptor (AhR) dependent genes in HaCaT cells. Journal of Investigative Dermatology 2009, 129:105. 17. Biziota E, Briasoulis E, Mavroeidis L, Marselos M, Pappas P. PPARg agonist rosiglitazone enhances the antiproliferative and anti-angiogenic profile of metronomic vinorelbine chemotherapy. European Journal of Cancer 2010, 8(5):72. 19. Gaitanis G, Galanou M, Magiatis P, Mexia N, Stathopoulou K, Skaltsounis A-L, Marselos M, Velegraki A, Bassukas ID, Pappas P. Malassezia Metabolites indirubin and malassezin are potent activators of the Aryl-hydrocarbon receptor (AhR) in HaCaT cells. Journal of Investigative Dermatology 2010, 130(S2):91. B. In Proceedings (More than 50). Full Papers
1. Pappas P, Vasiliou V, Nebert DW, Marselos M. Responses of rat liver cytosolic aldehyde dehydrogenase to toxic chemicals, glutathione depletion, and other forms of stress. Biochem Pharmacol. 1994, 48:841-845. 2. Pappas P, Vasiliou V, Karageorgou M, Stefanou P, Marselos M. Studies on the induction of rat class 3 aldehyde dehydrogenase. Adv Exp Med Biol. 1995, 372:143-149. 3. Pappas P, Stephanou P, Karamanakos P, Vasiliou V, Marselos M. Ontogenesis and expression of ALDH activity in the skin and the eye of the rat. Adv Exp Med Biol. 1997, 414:73-80. 4. Konstandi M, Pappas P, Johnson E, Lecklin A, Karageorgou M, Marselos M. Modification of reproductive function in the rat by 3-methylcholanthrene. Pharmacol Res. 1997, 35:107-111. 5. Konstandi M, Pappas P, Johnson E, Lecklin A, Marselos M. Suppression of the acquisition of conditioned avoidance behavior in the rat by 3-methylcholanthrene. Pharmacol Biochem Behav. 1997, 56:637-641. 6. Pappas P, Stephanou P, Vasiliou V, Marselos M. Anti-Inflammatory agents and inducibility of hepatic drug metabolism. Eur J Drug Metab Pharmacokinet. 1998, 23:457-460. 7. Pappas P, Stephanou P, Vasiliou V, Marselos M. Zoxazolamine paralysis in two substrains - Differences of hepatic drug metabolism. Eur J Drug Metab Pharmacokinet. 1998, 23:461-467. 8. Stephanou P, Konstandi M, Pappas P, Marselos M. Alterations in central monoaminergic neurotransmission induced by polycyclic aromatic hydrocarbons in rats. Eur J Drug Metab Pharmacokinet. 1998, 23:475-481. 9. Stephanou P, Pappas P, Vasiliou V, Marselos M. Prepubertal regulation of the rat dioxin-inducible aldehyde dehydrogenase. Adv Exp Med Biol. 1999, 463:143-150. 10. Pappas P, Stephanou P, Sotiropoulou M, Murphy C, Salminen L, Marselos M. Effects of tamoxifen and toremifene on ALDH1 and ALDH3 in human retinal pigment epithelial cells and rat liver. Adv Exp Med Biol. 1999, 463:151-158. 11. Sotiropoulou M, Pappas P, Marselos M. Effects of 3-methylcholanthrene and aspirin co-administration on ALDH3A1 in HepG2 cells. Chem Biol Interact. 2001, 130-132:235-245. 12. Pappas P, Stephanou P, Karamanakos P, Vasiliou V, Marselos M. Phenobarbital inducibility and differences in protein expression of an animal model. Chem Biol Interact. 2001, 130-132:275-283. 13. Karamanakos P, Pappas P, Stephanou P, Marselos M. Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism. Pharmacol Toxicol. 2001, 88:106-110. 14. Mannerstrom M, Zorn-Kruppa M, Diehl H, Engelke M, Toimela T, Maenpaa H, Huhtala A, Uusitalo H, Salminen L, Pappas P, Marselos M, Mantyla M, Mantyla E,Tahti H. Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells. Toxicol In Vitro. 2002, 16:193-200. 15. Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Nikolaidou M., Samonis G, Marselos M. Georgoulias V. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol 2003, 14:304-312. 16. Pappas P, Sotiropoulou M, Karamanakos P, Kostoula A, Levidiotou St, Marselos M. Acute phase response to benzo[α]pyrene and induction of rat ALDH3A1. Chem Biol Interact. 2003, 143-144:55-62. 17. Huhtala A, Alajuuma P, Burgalassi S, Chetoni P, Diehl H, Engelke M, Marselos M, Monti D, Pappas P, Saettone MF, Salminen L, Sotiropoulou M, Tahti H, Uusitalo H, Zorn-Kruppa M. A collaborative evaluation of the cytotoxicity of two surfactants by using the human corneal epithelial cell line and the WST-1 test. J Ocul Pharmacol Ther. 2003, 19:11-21. 18. Karamanakos PN, Pappas P, Marselos M. Involvement of the brain serotonergic system in the locomotor stimulant effects of chlorpheniramine in Wistar rats: implication of postsynaptic 5-HT1A receptors. Behav Brain Res. 2004, 148:199-208. 19. Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M. Pharmacokinetics of Imatinib Mesylate in End Stage Renal Disease. A case study. Cancer Chemother Pharmacol. 2005, 56(4):358-360. 20. Pappas P, Mavroudis D, Nikolaidou M, Georgoulias V, Marselos M. Co-administration of oxaliplatin does not influence the pharmacokinetics of gemcitabine. Anticancer Drugs. 2006, 17(10):1185-91. 21. Mitsou K, Koulianou A, Lambropoulou D, Pappas P, Albanis T, Lekka M. Growth rate effects, responses of antioxidant enzymes and metabolic fate of the herbicide Propanil in the aquatic plant Lemna minor. Chemosphere. 2006, 62(2):275-84. 22. Pentheroudakis G, Pappas P, Golfinopoulos V, Fountzilas G, Nikolaidou M, Boumba VA, Vougiouklakis T, Nikiforidis L, Tzamakou E, Siarabi O, Marselos M, Pavlidis N. Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy. Cancer Chemother Pharmacol. 2007, 60(5):733-9. 23. Bozionelou V, Vamvakas L, Pappas P, Agelaki S, Androulakis N, Kalykaki A, Nikolaidou M, Kentepozidis N, Giassas S, Marselos M, Georgoulias V, Mavroudis D. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. Br J Cancer. 2007, 2;97(1):43-9. 24. Karamanakos PN, Pappas P, Boumba VA, Thomas C, Malamas M, Vougiouklakis T, Marselos M. Pharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoamines. Int J Toxicol. 2007, 26(5):423-32. 25. Karamanakos PN, Pappas P, Marselos M. Comment on "Disulfiram-like effect of cyproterone acetate" [Z. Nitzan, M. Dan, Eur. J. Obstet. Gynecol. Reprod. Biol. (2007)]. Eur J Obstet Gynecol Reprod Biol. 2009, 146(2):237. 26. Kalbakis K, Pappas P, Kouroussis C, Vamvakas L, Kalykaki A, Vardakis N, Nikolaidou M, Marselos M, Georgoulias V, Mavroudis D. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008, 62(3):449-56. 27. Karamanakos PN, Pappas P, Marselos M. Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease. Pharm World Sci. 2008, 30(1):1-2. 28. Karamanakos PN, Pappas P, Marselos M. Disulfiram neuropathy: two cases of distal axonopathy. Clin Toxicol (Phila). 2008, 46(9):917-8. 29. Froudarakis ME, Pataka A, Pappas P, Anevlavis S, Argiana E, Nikolaidou M, Kouliatis G, Pozova S, Marselos M, Bouros D. Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. Cancer. 2008, 113(10):2752-60. 30. Karamanakos PN, Trafalis DT, Geromichalos GD, Pappas P, Harkitis P, Konstandi M, Marselos M. Inhibition of rat hepatic CYP2E1 by quinacrine: molecular modeling investigation and effects on 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced mutagenicity. Arch Toxicol. 2009, 83(6):571-80. 31. Saridaki Z, Pappas P, Souglakos J, Nikolaidou M, Vardakis N, Kotsakis A, Marselos M, Georgoulias V, Mavroudis D. A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009, 65(1):121-8. 32. Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, Pavlidis N. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res. 2009, 15(20):6454-61.

Source: http://www.materials.uoi.gr/polymers/Thalis/Medicine/PAPPAS_CV.pdf